Buscar
Rxsight Inc
RXSTAñadir a la lista de seguimiento
5.610USD
+0.440+8.51%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
232.23MCap. mercado
PérdidaP/E TTM
Más Datos de Rxsight Inc Compañía
RxSight, Inc. is a commercial-stage medical technology company dedicated to providing customized vision to patients following cataract surgery. The Company's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.
Información de Rxsight Inc
Símbolo de cotizaciónRXST
Nombre de la empresaRxsight Inc
Fecha de salida a bolsaJul 30, 2021
Director ejecutivoKurtz (Ron M)
Número de empleados498
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 30
Dirección100 Columbia Street
CiudadALISO VIEJO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92656
Teléfono19495217822
Sitio Webhttps://www.rxsight.com/
Símbolo de cotizaciónRXST
Fecha de salida a bolsaJul 30, 2021
Director ejecutivoKurtz (Ron M)
Ejecutivos de Rxsight Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Eric Weinberg
Mr. Eric Weinberg
Co-President, Chief Commercial Officer
Co-President, Chief Commercial Officer
497.92K
+0.33%
Dr. William J. Link, Ph.D.
Dr. William J. Link, Ph.D.
Independent Director
Independent Director
96.14K
+38.52%
Dr. Ilya Goldshleger, Ph.D.
Dr. Ilya Goldshleger, Ph.D.
Co-President, Chief Operating Officer
Co-President, Chief Operating Officer
79.55K
+15.70%
Mr. Robert J. (Bob) Palmisano
Mr. Robert J. (Bob) Palmisano
Independent Director
Independent Director
78.08K
+47.44%
Ms. Shweta Singh Maniar
Ms. Shweta Singh Maniar
Independent Director
Independent Director
55.17K
+67.13%
Ms. Shelley B. Thunen
Ms. Shelley B. Thunen
Co-President, Chief Financial Officer
Co-President, Chief Financial Officer
39.45K
+2.79%
Mr. J. Andy Corley
Mr. J. Andy Corley
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Ron M. Kurtz, M.D.
Dr. Ron M. Kurtz, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Robert K. Warner
Mr. Robert K. Warner
Independent Director
Independent Director
--
--
Ms. Julie B. Andrews
Ms. Julie B. Andrews
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Eric Weinberg
Mr. Eric Weinberg
Co-President, Chief Commercial Officer
Co-President, Chief Commercial Officer
497.92K
+0.33%
Dr. William J. Link, Ph.D.
Dr. William J. Link, Ph.D.
Independent Director
Independent Director
96.14K
+38.52%
Dr. Ilya Goldshleger, Ph.D.
Dr. Ilya Goldshleger, Ph.D.
Co-President, Chief Operating Officer
Co-President, Chief Operating Officer
79.55K
+15.70%
Mr. Robert J. (Bob) Palmisano
Mr. Robert J. (Bob) Palmisano
Independent Director
Independent Director
78.08K
+47.44%
Ms. Shweta Singh Maniar
Ms. Shweta Singh Maniar
Independent Director
Independent Director
55.17K
+67.13%
Ms. Shelley B. Thunen
Ms. Shelley B. Thunen
Co-President, Chief Financial Officer
Co-President, Chief Financial Officer
39.45K
+2.79%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Rxsight Inc?
Los cinco principales accionistas de Rxsight Inc son: Mr. Eric Weinberg
¿Cuántas instituciones poseen acciones de Rxsight Inc (RXST)?
A fecha de 2026Q1, 467 instituciones poseen acciones de Rxsight Inc, con un valor de mercado combinado de aproximadamente 38.60M, lo que representa el 93.24% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -10991579.00.